Moberg Pharma is a Swedish specialty pharma company primarily focusing on dermatology products in the OTC segment, with strong market positions in selected niche segments. In addition, Moberg Pharma has two clinical projects. Moberg Pharma has its own sales and marketing organisation in the US and relies on a handful of distribution partners in the other regions. Moberg Pharma has expanded its product offering through a number of acquisitions.
The roll-out of Moberg Pharma’s products in Asia could potentially be more successful than we have expected, but the main opportunity for Moberg Pharma is in the research pipeline with the two clinical projects, Mob-15 and BUPI, which could both surprise positively.
We note a number of risk factors for Moberg Pharma, including commercial risk, clinical and product development risk and regulatory risk. In addition, Moberg Pharma is dependent on distribution partners in markets outside of the US.